Thys Cronje, founder of Diacoustic Medical Devices
Thys Cronje created one of the teams that will move on to the next round of judging in the M2D2 contest. His company, Diacoustic Medical Devices, was chosen from the pool of applicants because of its true potential to disrupt medicine.
What is Diacoustic Medical Devices all about? This innovator describes his company in a MedTech Boston Q&A:
1. Briefly describe your technology.
SensiCardiac is a FDA cleared software application that assist physicians or physical examiners to distinguish between those hard to hear cardiac murmurs when auscultating. The software connects with the latest off-the-shelf electronic stethoscopes and is able to run on a Windows PC or an iPhone. After recording 20 seconds of heart sound at the four main auscultation locations SensiCardiac will determine if the murmur is a Class I or Class III echo-cardiography referral according to the AHA/ACC guidelines. Thus, determining if the murmur is due to a structural cardiac defect or an innocent murmur. It also goes one step further by indicating where the murmur is located within the heart beat’s systolic and diastolic segments.
2. How does it add value to a clinical environment?
Cardiac auscultation with a stethoscope is known to be subjective and a skill that requires years of experience to master, even for cardiologists who does it every day. SensiCardiac enables a primary care physician to perform a cardiac assessment with the same accuracy as a cardiologist, resulting in an objective decision and providing a patient peace of mind. This technology could have a huge cost impact by reducing the more than 60% of unnecessary referrals to cardiologists due to innocent murmurs. Diagnosing structural cardiac defects earlier in a patients life could also have a big impact on the patient’s quality of life.
3. How is it disruptive?
SensiCardiac, engineered to outperform a cardiologist, is the most advanced auscultation technology currently available on the market. This technology will change the way physicians are using the 200 year old stethoscope when assessing cardiac sounds. The advance in processing, communication and mobile technology opened the door to not only perform the advanced heart sound signal processing on a mobile device, but also in the cloud.
SensiCardiac is going one step further by beautifully integrating the various platforms (PC’s and iPhone) through the same cloud interface, allowing the physicians to access the patients’ auscultation results where ever they go.
4. What is your target market?
The target market are those clinicians that regularly perform physical assessments and auscultate the heart for abnormal sounds. This includes family physicians, pediatricians, nurse practitioners, physician assistants and even chiropractors that are performing routine physical assessments, DOT physical examinations, pre-participation athletic screenings, summer camp physicals, college physicals, as well as emergency care assessments.
5. What are your anticipated funding needs?
Our anticipated funding needs are $1.2M.
Congratulations and good luck to Diacoustic Medical Devices, and be sure to stay tuned to catch the other 14 finalists winners featured on MedTech Boston!M2D2 will be hosting the 2014 New Venture Competition Showcase Event on Wednesday, March 26, 2014. Novel medical device technologies will be presented, followed by a poster and networking session. The grand prize winner will be announced at the follow up winner’s ceremony on April 8th at the offices of Nutter McClennen & Fish in Boston from 4 pm to 8 pm.
At MedTechBoston, we are sharing stories about cutting-edge medical innovation. As Managing Editor, I help coordinate our coverage of hackathons and company profiles. I also create content, update our social media and scout stories. I'm part of an ambitious group of people hoping to inspire a tech revolution in medical care.
Send this to friend